A5088053552- Quinazolinone synthesis and applications
- Chronic Myeloid Leukemia Treatments
- Eosinophilic Disorders and Syndromes
- Synthesis and Characterization of Heterocyclic Compounds
- Biochemical and Molecular Research
- Fungal Plant Pathogen Control
- Crystallization and Solubility Studies
- Chronic Lymphocytic Leukemia Research
- X-ray Diffraction in Crystallography
Fundação Oswaldo Cruz
2020-2022
Instituto de Tecnologia e Pesquisa
2022
The enzyme tyrosine kinase BCR-Abl-1 is the main molecular target in treatment of chronic myeloid leukemia and can be competitively inhibited by inhibitors such as imatinib. New potential competitive were synthesized using (phenylamino)pyrimidine-pyridine (PAPP) group a pharmacophoric fragment, these compounds biologically evaluated. synthesis twelve new was performed three steps assisted microwave irradiation 1,3-dipolar cycloaddition to obtain 1,2,3-triazole derivatives substituted on...
Imatinib (IMT) is the first-in-class BCR-ABL commercial tyrosine kinase inhibitor (TKI). However, resistance and toxicity associated with use of IMT highlight importance search for new TKIs. In this context, heterocyclic systems, such as quinoline, which present a pharmacophore in structure TKI bosutinib (BST), have been widely applied. Thus, work aimed to obtain hybrids imatinib containing quinoline moieties evaluate them against K562 cells. The compounds were synthesized high purity...
The enzyme tyrosine kinase Bcr-Abl-1 is the main molecular target in treatment of chronic myeloid leukemia and can be competitively inhibited by inhibitors such as imatinib. New potential competitive were synthesized using phenylamino pyrimidine pyridine (PAPP) group a pharmacophoric fragment, these compounds biologically evaluated. synthesis twelve new was performed three steps assisted microwave irradiation 1,3-dipolar cycloaddition to obtain 1,2,3-triazole derivatives substituted on...